Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-04-24 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
苏州浩欧博生物医药销售有限公司2021年年度财务报表
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets with assets, liabilities, and equity, as well as income statement items such as revenue, costs, expenses, and net profit. It also includes notes to the financial statements and signatures of responsible persons. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content is consistent with a comprehensive annual financial report covering company activity and full financial performance. There is no indication that this is a partial or quarterly report, nor is it a mere announcement or certification. Therefore, the document is best classified as an Annual Report (10-K). FY 2023
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司第二届第15次董事会独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from independent directors regarding various proposals to be submitted to the 2021 Annual General Meeting (AGM) of Jiangsu Haobo Biopharmaceutical Co., Ltd. It covers opinions on the reappointment of the 2022 audit firm, the 2021 profit distribution plan, the 2021 internal control evaluation report, the 2022 guarantee limit, the 2022 directors and senior management remuneration, and the 2021 raised funds usage report. The document is not the actual audit report, annual report, or financial statements but rather an independent directors' opinion on matters to be voted on at the AGM. It is a governance-related document providing independent directors' views on board meeting agenda items. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on governance and management proposals.
2022-04-24 Chinese
华泰联合证券关于对江苏浩欧博生物医药股份有限公司2021年度募集资金存放和使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年度募集资金存放和使用情况专项核查报告" which translates to "2021 Annual Special Inspection Report on the Deposit and Use of Raised Funds". It is issued by 华泰联合证券有限责任公司, the sponsor institution, and includes detailed information about the amount of funds raised, their usage, management, and verification by an accounting firm. The document focuses on the management and use of funds raised from a public offering, including compliance with regulatory requirements and internal controls. It is not a full annual report or financial statement but a specialized audit or verification report on the use of raised capital. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific regulatory requirements, excluding full annual reports. The document length (7337 characters) and detailed financial data support this classification rather than a brief announcement or a general regulatory filing. FY 2021
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于对外担保情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the fiscal year 2021. It references regulatory requirements from the China Securities Regulatory Commission and details the amounts, dates, and parties involved in the guarantees. The document is a focused disclosure on external guarantees, not a full financial report or audit. It is relatively short (1381 characters) and does not contain comprehensive financial statements or management discussion. It is not an announcement of a report but a standalone statement fulfilling regulatory disclosure requirements. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告及财务报表' which translates to 'Audit Report and Financial Statements' for the fiscal year 2021. It includes detailed audit opinions, key audit matters, and extensive financial statements such as consolidated balance sheets, income statements, cash flow statements, and notes to the financial statements. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2021
2022-04-24 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于第二届董事会第十五次会议相关事项的事前认可意见
Regulatory Filings Classification · 90% confidence The document is a statement from independent directors regarding their prior approval opinion on matters to be submitted to the company's board meeting, specifically about the proposal to reappoint the audit firm for the 2022 fiscal year. It references regulatory rules related to independent directors and corporate governance but does not contain actual financial statements or audit results. The document is short (1149 characters) and serves as an opinion or approval related to audit matters rather than the audit report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a governance-related announcement that does not fit the standalone audit report category (AR) or other specific categories.
2022-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.